Magdalena Jaglinska

Experimental Psychology, University College London, London, UK.

2 papers in the library · publishing 2025-2026

Papers

Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers.

BMJ open March 12, 2026 Rosalind McAlpine, Magdalena Jaglinska, Krisztina Jedlovszky et al.

A 21-day mobile-accessible programme called the Digital Intervention for Psychedelic Preparation (DIPP) is being tested for feasibility and preliminary efficacy in a randomised controlled trial. The study will recruit 40 non-treatment-seeking adults without a clinical diagnosis, randomly assigning them to either a guided meditation with music condition or a music-only condition. After the digital intervention, all participants will attend an in-person supervised psilocybin session with a standardised 25 mg dose. Primary outcomes include recruitment efficiency, retention, and adherence; secondary outcomes assess preparedness, quality of the psychedelic experience, and wellbeing, with follow-ups up to 9 months. The trial is registered as NCT06815653.

DOI: 10.1136/bmjopen-2025-107512 Full text Clinical protocols Psychiatry Randomized controlled trial Telemedicine

Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial

November 16, 2025 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. preprint

A phase II trial will test whether microdosing psilocybin (2 mg weekly) outperforms placebo for major depressive disorder. Forty adults will receive either psilocybin or placebo for four weeks, then all will receive psilocybin for another four weeks. Depression symptoms and other measures will be assessed at baseline, after four weeks, and after eight weeks, with follow-ups for two years. The study aims to clarify whether microdosing has genuine antidepressant effects or whether benefits are due to expectancy, and to inform future dose regimens and the therapeutic role of sub-threshold versus threshold doses.

DOI: 10.31234/osf.io/hmnsw_v1 Psilocybin Major depressive disorder Anxiety Placebo +15